The purpose of this study to is to assess the feasibility and acceptability of using a point-of-care (POC) prostate specific antigen (PSA) test to screen men for prostate cancer in a community setting.

In this study, participants will receive a fingerstick blood draw from a research nurse at the barbershop and results will be shared with the participants.
   
Participation is expected to last up to 6 months.

The purpose of this study is to evaluate the safety and effectiveness of bright light therapy for patients with melanoma and non-small cell lung cancer (NSCLC).

In this study, bright light therapy will be provided via an iPad at the participant's home for 60 minutes total.
   
Participation is expected to last 3 weeks.

This clinical trial is for adults who have relapsed/refractory acute lymphoblastic leukemia (ALL) and the Obe-Cel product prescribed by their study doctor did not meet commercial release criteria.

The purpose of this Out-Of-Specification (OOS) Obecabtagene-Autoleucel (Obe-Cel) Early Access Program (EAP) is to make Obe-Cel OOS available for adult patients with relapsed or refractory B-cell ALL who have had leukapheresis. This program will also gather real-world safety data to check how safe the experimental intervention with Obe-Cel OOS is.

This clinical trial is for adults who have blood cancer or precancerous conditions that are highly likely to turn into blood cancer.

The purpose of this study is to answer the following primary questions:

The purpose of this study is to compare the effectiveness of 6 months of HER2-targeted medications (trastuzumab with or without pertuzumab) versus 12 months of HER2-targeted medications at reducing the risk of breast cancer coming back or death in patients with early-stage HER2+ breast cancer who had a pCR after preoperative chemotherapy combined with trastuzumab.

This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach.

The purpose of this pilot study is to evaluate a new decision support tool (“COAST”), designed for people with advanced breast cancer. This tool is intended to support patients and their providers to have meaningful conversations regarding their care and treatment. Through this study, we hope to better understand and improve our support of patients in making informed choices about their treatment.

The COAST decision support tool is available in a booklet version and a website based on preference. 

This study is being done to determine if the addition of a high dose of radiation therapy extends or improves quality of life in patients with locally advanced pancreatic cancer. Locally advanced means that the cancer cannot be removed by surgery but also has not spread to other parts of the body and the tumor has either responded or is stable after chemotherapy.

We are doing this study because we want to find out if this approach is better or worse than the usual approach, which is defined as care most people get for locally advanced pancreatic cancer. 

This is a prospective observational study of clinical and patient-provided outcomes for individuals with sex chromosome aneuploidy (SCA) conditions throughout the lifespan: the GALAXY Registry.

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).
   
The BioHealx implant is a small coil made of a material that is absorbed by the body over time. It has been designed to close the fistula. As the fistula heals, the implant gradually dissolves from the body.
   

 This clinical trial is for men and women with HR+/HER2− stage II or III eBC patients treated with the study drugs, i.e., Kisqali® (ribociclib) + endocrine therapy (ET), or Verzenio® (abemaciclib) + ET, as per local label in routine clinical care settings.
   
The purpose of this study to learn more about how people with early breast cancer feel and respond when treated with either Kisqali® (ribociclib) plus ET or Verzenio® (abemaciclib) plus ET treatment.